Journal of Advanced Scientific Research

Available online through https://sciensage.info

ISSN

0976-9595

Review Article

Revolutionizing Early Diagnosis: The Role of Artificial Intelligence in Neurodegenerative Disorders

Shivam Pal, Archit Kaushik, Falguni Goel, Akansha Pal, Vipin Kumar Garg*

Department of Pharmaceutical Technology, Meerut Institute of Engineering & Technology (MIET), Meerut, Uttar Pradesh, India.

*Corresponding author: vipin3005@yahoo.com

Received: 16-02-2025; Accepted: 22-02-2025; Published: 29-03-2025

https://doi.org/10.55218/JASR.2025160306

ABSTRACT

There has been an increase in the prevalence of neurodegenerative diseases among the elderly population in recent years. AI methods can help with fast and accurate diagnosis of numerous diseases, enabling quick interventions and personalized treatment plans. Predicting prognosis and disease progression, these algorithms provide valuable information on disease pathways and clinical decision-making. AI-powered image analysis techniques detect biomarkers linked to illnesses by recognizing subtle alterations in the brain's structure and operation. Clinical trials and drug development rely on biomarkers like these as they allow for quick intervention and provide unbiased evaluations of treatment success. AI has the great capacity to change how we identify and treat neurodegenerative diseases, playing a crucial role in advancing successful treatments and enhancing patient care. There are few treatment choices available for numerous neurodegenerative disorders because there are not enough early diagnostic methods that enable the timely administration of medications to damaged neurons before they die. Although significant progress has been achieved in neurodegenerative disease biomarkers, it is still uncertain if the biomarkers identified so far can be beneficial for early detection. Furthermore, the trustworthiness of these biomarkers has been unsatisfactory, because of the significant differences between the tissues typically utilized for biomarker identification and predominantly affected neurons. This article discusses the possible effectiveness of unusual epigenetic and resulting transcriptional changes as indicators of early neurodegenerative disease and offers insights into finding and using these indicators in neural samples from patients to single cell level, which significantly improves the accuracy of using biomarkers.

Keywords: Artificial intelligence, Alzheimer's disease, Epilepsy, Parkinson's disease, Multiple sclerosis, Diagnosis, Future directions.

INTRODUCTION

Neurodegenerative conditions like Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis are typified by cumulative neuronal dysfunction that finally results in cognitive as well as motor dysfunction. Neurodegenerative diseases have a very large burden on the patient, family, and healthcare system at large[1]. Early diagnosis has never been a key feature of the management of such cases because it will enhance the patient outcome by offering early intervention, which will retard the progress of disease and quality of life improvement as well. The conventional approach to diagnosis is, however, besieged by a myriad of drawbacks that render its ability to diagnose these conditions early impossible[2].

Traditional diagnoses of neurodegenerative diseases rely on clinical evaluation, imaging, and biomarker examination. Traditional methods are marred by limitations like the subjectivity in symptom-based grading, the expense and limited availability of newer imaging techniques, and the nonexistence of suitably well-above-average-mark biomarkers to be found early[3]. Therefore, most patients are diagnosed with complete confidence only after an extensive neurological deficit has been accumulated as a result of the disease, reducing the achievable therapeutic effect[4].

In the last two years, artificial intelligence has been a game-changer technology in the medical sector with advanced solutions to improve the accuracy and speed of diagnostics. AI-based algorithms, machine learning models, and deep learning models have been proven to interpret intricate medical information, like brain images, genetic information, and patient history, with unparalleled precision. Such technologies must be capable of picking up more subtle patterns that the human clinician might otherwise overlook, thus leading to earlier and more effective diagnosis of neurodegenerative disease[5]. Through the use of AI in a clinical environment, the doctor can take a step further to active treatment, thereby facilitating better management of the patient as well as further research into such debilitating illnesses.[6]

Neurodegenerative Disorders

Neurodegenerative diseases are a group of diseases causing progressive nerve cell degeneration resulting in mental impairment, motor impairment, and other nervous system impairments. Some of the most common among them include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) (Figure 1). The diseases significantly impact the lifestyle of patients



Figure 1: The spectrum of neurological disease taken from Alzheimer's and Parkinson's to epilepsies and multiple sclerosis: comprehending these disorders is a prerequisite for coming up with treatments and for enhancement of lives

increasingly causing loss of dependency and significantly burdening patients, as well as caregivers and healthcare systems[7].

Alzheimer's is the most common form of memory, thinking, and behavior-based core functions with dementia. It is caused by the accumulation of the brain's beta-amyloid plaques and tau protein tangles and subsequently degenerating neurons and brain shrinkage.[8] Parkinson's disease is a movement disorder resulting from progressive loss of dopaminergic neurons of the substantia nigra and leading to tremor, rigidity, and bradykinesia. Both ALS and Huntington's disease, for example, share selective neuronal death with variable distinctive individual clinical presentations with identical neurodegenerative pathogenetic mechanisms[9].

Pathophysiology of the conditions is complex and usually an interplay of genetic, environmental, and molecular factors. Primary mechanisms for the progression of disease are protein misfolding and aggregation, mitochondrial failure, oxidative damage, and inflammation. As the progression of function by neurons is more, the compensation capacity of the brain reduces, and the progression of the symptoms keeps going on[10]. In spite of increased knowledge of these mechanisms, therapeutically effective disease-modifying therapy remains to be found, and this underscores the importance of early diagnosis for improved management and possible therapeutic intervention[11].

Current diagnostic techniques for neurodegenerative illnesses include imaging, screening for biomarkers, and clinical assessment. Symptoms are examined by clinicians with neurological examination and cognitive assessment but tend to be subjective and too insensitive to pick up the disease upon initial occurrence. Imaging modalities such as MRI, PET, and CT scan are helpful in identifying structural and functional changes in the brain but are expensive and not necessarily universally available[12]. Moreover, cerebrospinal fluid and blood biomarkers are also under investigation as detection methods in the early stages, but these are not yet used clinically. Due to these constraints, most of the patients are diagnosed only after a lot of damage is caused to the neurons, hence there is a need for improved diagnostic tools that can identify neurodegenerative disease early and more accurately[13].

Artificial Intelligence in Medical Diagnostics

Artificial intelligence in clinical diagnosis refers to the use of computer algorithms and complex data processing technologies for medical data analysis, pattern recognition, and enhancement of clinical decision-making. AI is an array of tools like machine learning, deep learning, and neural networks that could revolutionize health care to improve diagnostic accuracy, efficacy, and accessibility. With the deployment of big data, AI programs can identify the markers of a disease, predict the fate of patients, and help healthcare providers make informed choices (Figure 2).[14]

Machine learning is one of the domain areas of AI in which systems can learn and enhance performance over a period without being programmed. Machine learning is training big volumes of healthcare data such as imaging exams, genomic data, and computerized patient data into learning patterns for the purpose of detecting disease. Deep learning is an advanced and new type of machine learning that utilizes artificial neural networks that can imitate the capability and structure of the human brain.[15] The networks can process highly dimensional and complicated information and are being utilized heavily in medicine imaging, pathology, and genomics. The most utilized networks in healthcare are recurrent neural networks and convolutional neural networks, resulting in accurate radiological image interpretation, electroencephalograms, and diagnostic testing results[16].

The uses of AI in medicine extend beyond diagnosis to other purposes such as targeted therapy, drug discovery, and patient monitoring. Machine learning computers assisted by AI assist radiologists in detecting abnormalities in medical images, reducing the risk of misdiagnosis and increasing efficiency (Table 1). In neurology, AI computers scan brain images for evidence of neurodegenerative diseases, facilitating early intervention. In addition, predictive models based on AI aid disease progression and treatment response, making personalized patient care possible. With subsequent developments in technology, clinical diagnosis using AI will further consolidate healthcare provision, improve patient outcomes, and assist in overcoming the current challenges of disease detection and management.[17]

AI Applications in Early Diagnosis of Neurodegenerative Disorders

Artificial intelligence has emerged to play a key role in early neurodegenerative disease diagnosis by maximizing the accuracy and efficiency of various diagnostic tests. Imaging diagnosis is the most



Figure 2: It's related to the fact that neurodegenerative disorders will be revolutionized by using algorithms powered by AI for early detection. They will promptly initiate an intervention and will see better outcomes in patients

Table 1: Artificial intelligence in medical diagnostics

Aspect	*Details*	*References*
Definition	The use of AI algorithms and machine learning models to assist in identifying diseases, analyzing medical data, and improving diagnostic accuracy.	[18]
Key Technologies	Machine learning (ML), deep learning (DL), natural language processing (NLP), computer vision, neural networks.	[19]
Applications	Disease detection (e.g., cancer, COVID-19), medical imaging (X-rays, MRIs, CT scans), pathology, genetic analysis, and predictive analytics.	[20]
Advantages	Faster diagnosis, improved accuracy, reduction in human error, early disease detection, and enhanced decision-making support.	[21]
Challenges	Data privacy concerns need for high-quality training data, regulatory compliance, ethical considerations, and potential biases in AI models.	[22]
Examples	AI-powered radiology tools (e.g., detecting tumors in CT scans), IBM Watson for Oncology, and Google's DeepMind for eye disease detection.	[23]
Future Trends	Integration with wearable devices, AI-driven personalized medicine, automated medical record analysis, and real-time diagnostics through AI-powered chatbots.	[24]

important application of AI wherein machine models learn from MRI, PET, and CT scans to diagnose the minute structural and functional brain alterations. These imaging modalities are helpful in yielding information regarding neurodegeneration but are time-consuming to analyze and susceptible to human interpretational mistakes[25]. Large image databases can be employed to train algorithms to identify patterns of diseases such as Alzheimer's and Parkinson's at an early stage, even before the development of clinical features. Deep models, such as convolutional neural networks, have performed best in brain atrophy, amyloid plaque, and other biomarkers from neuroimaging scans[26].

Aside from imaging, AI has also proven very promising for biomarker analysis, including the detection of disease-related biological markers in blood, cerebrospinal fluid (CSF), and genomic information. The conventional means of biomarker testing are costly and invasive and hence not performed on a wide scale. Artificial intelligence computing supports big data processing for the biochemical and genetic putative biomarkers identification to function as predictors of neurodegenerative disease.[27] Machine learning algorithms, for example, can be applied to screen for genetic variation that has been implicated in diseases such as Alzheimer's and return risk factor determination and intervention sooner. AI-based CSF and blood sample analysis also enables the identification of abnormal protein deposits like beta-amyloid and tau, which are particular to neurodegenerative disease.[28]

Along with biological markers, AI penetrated speech and gait analysis more and more, offering less invasive, cheaper early diagnosis. Speech features like altered pitch, stuttering, and slowness of speech are preclinical indicators of conditions like Parkinson's and ALS. AI speech models analyze recordings of voice to detect these subtle changes and assist with their identification. Similarly, gait impairments, i.e., changes in walking speed, stride length, and balance, are prodromal symptoms of neurodegenerative conditions. Motion analysis systems and AI-enabled wearable sensors can longitudinally monitor and assess gait patterns and enable early diagnosis and tracking of disease development.[29]

AI also plays a key role in cognitive and behavioral assessments that are vital in the early detection of neurodegenerative illnesses. Traditional cognitive tests rely on subjective evaluation, and hence it is hard to identify these conditions early. AI-driven technologies analyze cognitive function patterns, memory, and decision-making abilities through computerized tests and natural language processing. Machine learning algorithms can identify abnormal cognitive performance by processing data from computerized tests, smartphone applications, and daily interactions.[30] Additionally, AI systems quantify shifts in behavior, such as social interaction and emotional reactivity, that are potential prodromal signs of Alzheimer's and frontotemporal dementia. By using AI for comprehensive cognitive and behavioral assessment, early identification is more feasible, allowing for timely intervention and improved patient outcomes[31].

Advantages of AI in Neurodegenerative Disorder Diagnosis

Artificial intelligence has enhanced neurodegenerative disease diagnosis significantly by enhancing sensitivity and accuracy in detecting the initial presentation of the disease. Standard diagnosis is founded on very subjective clinical rating and imaging interpretation and these are unreliable for diagnosis. Algorisms built using AI, and even better with deep learning and machine learning, analyze sets of intricate information with very high accuracy and reduce misdiagnosis[30]. With the identification of minimal changes in brain anatomy, levels of biomarkers, speech, and movement function, AI enables more reproducible and objective examination. With greater precision, differentiation between overlapping syndromes and neurodegenerative illnesses and thus prescribe focused therapy and management (Table 2).[32]

The other major advantage of AI in diagnosing neurodegenerative diseases is that it is quicker and cheaper. Conventional diagnosis machines such as PET scans, genetic tests, and biomarker examinations are costly, time-consuming, and not standard in hospitals. AI reduces data interpretation and processing, and this is time-saving for analyzing medical images, laboratory tests, and patient history.[33] With diagnostic simplification, not only is the health worker's burden eliminated but early detection is facilitated in resource-constrained settings. In addition, AI-powered apps embedded in wearables and smartphones facilitate low-cost continuous monitoring, and initial

signs of neurodegeneration are detected without the need to make repeated hospitalizations.[34]

Arguably most groundbreaking advantage of AI within this area is that it can potentially identify early, before symptomology clinically. With many neurodegenerative diseases, e.g., Alzheimer's and Parkinson's, running stealthily for years on end before showing symptoms, early intervention being the problem, this is no trivial problem. AI algorithms developed through massive databases have the ability to recognize subtle physiological and behavioral changes that would characterize the onset of a disorder long before conventional methods, which would get caught up with it.[35] For instance, AI-powered speech, handwriting, eye tracking, and gait analysis are able to identify early abnormalities that might otherwise go unobserved. With the aid of pre-symptomatic diagnosis, AI allows an individual to initiate medical treatment, life adjustment, and, potentially, clinical trial entry in a timely manner, thereby resulting in enhanced disease management and patient condition.[36]

Challenges and Limitations of AI in Early Diagnosis

Although enormous potential exists for artificial intelligence in the early detection of neurodegenerative disorders, several challenges and limitations must be overcome to harness its successful application in the clinic. The most common problem is the quality and amount of data employed in training AI platforms. Machine learning algorithms require leveraging gigantic and heterogeneous data to learn neurodegenerative disease patterns well. However, clinical data, particularly neurology, typically is constrained by the intricacies of brain imaging, biomarker tests, and patient heterogeneity. Data aggregated from different sources may also be of varying qualities and thus possibly difficult to craft strong AI algorithms that perform similarly across populations.[30]

In addition, the discrepancy of accessible data sets, where more advanced-stage cases than early-stage cases, can restrict the ability of AI to recognize pre-symptomatic signs of these disorders effectively. Ethics and privacy concerns are the greatest challenges in using AI for early detection. The use of AI in medicine involves access to private patient information, including medical history, genetic data, and imaging tests. Keeping data secure from breaches and the confidentiality of patients is critical, as breaches of medical information can result in severe consequences.[46]

This is further accompanied by algorithmic bias as a threat in the sense that AI models under representative datasets provide unbalanced or inaccurate results targeting specific groups unequally. Ethical undertones are further extended to unintended psychological harm arising from early diagnosis in the sense that patients diagnosed with neurodegenerative diseases before actually showing symptoms of the disease can experience anxiety and distress without accompanying treatment. Establishing ethical norms and regulatory standards is required to counter these challenges and ensure responsible AI deployment in healthcare.[47]

Future Directions and Innovations

The second significant limitation is the need for extensive clinical trials and seamless interfacing of AI solutions with existing clinical practices. Although AI has demonstrated positive outcomes in controlled environments, universal adaptation in actual clinical settings requires strong validation by running clinical trials. AI models should be tested across a large cohort of patients and disease states in order for them to be meaningful and trustworthy. Additionally, applying AI to routine clinical practice requires collaboration between healthcare professionals and technology designers[48]. Clinicians will not have the requisite knowledge to understand AI-calculated results, and resistance to adoption based on

Table 2: Advantages of AI in neurodegenerative disorder diagnosis

Advantage	*Details*	*References*
Early detection	AI can identify subtle patterns in brain scans and biomarkers, enabling early diagnosis of conditions like Alzheimer's, Parkinson's, and ALS.	[37]
Improved accuracy	Machine learning models analyze vast amounts of data with high precision, reducing human error in diagnosis.	[38]
Non-invasive techniques	AI-driven tools use imaging (MRI, PET, CT) and biomarker analysis, reducing the need for invasive procedures like biopsies.	[39]
Personalized treatment	AI can analyze genetic and clinical data to recommend tailored treatment plans for individual patients.	[40]
Efficient data processing	AI can process large datasets quickly, identifying disease patterns and trends faster than traditional methods.	[41]
Remote monitoring	AI-powered wearable devices and mobile apps can track disease progression and patient health in real-time.	[42]
Predictive analytics	AI models can forecast disease progression, allowing for proactive interventions and better patient management.	[43]
Reduction in diagnostic time	AI-assisted analysis reduces the time needed for doctors to interpret scans and medical records.	[18]
Integration with electronic health records (EHRs)	AI streamlines access to patient histories, improving continuity of care and aiding in longitudinal studies.	[44]
Drug discovery support	AI aids in identifying potential drug candidates and predicting their effectiveness for neurodegenerative diseases.	[45]



Figure 3: The Future of AI tomorrow in early diagnosis of neurodegenerative disorders: Advancing precision, personalization, and predictive care

issues with accuracy, accountability, and perturbation of practices can be anticipated. Resolution of these issues through clinician training, regulatory endorsement, and interdisciplinary planning is necessary for AI to be a beneficial and reliable tool in early neurodegenerative disease diagnosis (Figure 3).[49]

The future of AI for diagnosing neurodegenerative disease appears bright to see incredible progress, as researchers are working on refining the accuracy, performance, and ease of use of AI-based diagnostic platforms. Perhaps the most significant research areas are in the development of more advanced AI algorithms capable of managing multimodal and multiform data. Deep learning, reinforcement learning, and explainable AI future trends will make AI models and their choices understandable to become transparent and trustworthy[50]. Multimodal data sources like neuroimaging, genetics, voice, and changes in behavior will enable AI to give a richer and more comprehensive assessment of neurodegenerative disorders.

Furthermore, the decentralized AI training method, federated learning, enables multiple institutions to work together to develop strong AI models without breaching patient data privacy, allowing for greater generalizability and scalability of AI solutions. Yet another potential area is that of personalized medicine, where AI-based systems can provide diagnosis and treatment on an individual basis to a specific patient. Neurodegenerative diseases are very heterogeneous in terms of symptomatology, disease course, and response to treatment, and personalized treatment is best suited to improve patient care[51]. AI can be utilized to harness genetic, biochemical, and lifestyle information in order to forecast the probability of an individual contracting a disorder and offer targeted interventions. In addition, AI algorithms can tailor treatment regimens by predictive modeling of a patient's reaction to a particular drug or intervention, thus obviating the trial and error involved in the management of a disease. With progress in precision medicine, AI is pioneering the way to create individualized therapy for neurodegenerative disease to improve patient outcomes and quality of life.[52]

CONCLUSION

The combination of AI with remote and wearable monitoring sensors is another wide technology that is transforming early diagnosis and chronic disease management. Wearable sensors like smartwatches, movement sensors, and voice analysis software provide real-time tracking of behavioral and physiological markers of neurodegenerative disorders. Interpreted, data from such sensors can be monitored with AI to mark nuanced changes in movement, speech, and cognitive function to diagnose the onset and advancement of disease earlier. Preventative treatment is also enabled by remote monitoring with doctors being able to keep track of patients twenty-four-seven without having to constantly call them back and forth between hospital wards. This is particularly useful for patients who are distant from or in rural areas and might not readily have access to specialist neurological evaluation. With the next-generation AI-driven wearables, there is hope for transforming early detection, disease tracking, and tailored adaptation of the management of neurodegenerative diseases, with more and quicker medical care.

Artificial intelligence has been a revolutionary force in the early detection of neurodegenerative diseases by overcoming the sheer majority of the limitations of traditional diagnostic methods. Sophisticated machine learning algorithms employed by AI enhance the precision, sensitivity, and speed of detecting early disease biomarkers, typically before the onset of clinical symptoms.[53] AI-powered neuroimaging analysis, biomarker recognition, speech and gait processing, and mental tests are less subjective and complete means of illness diagnosis such as Alzheimer's and Parkinson's illness[53]. This not only gives the potentiality of early healthcare treatment but also improves patient performance through enhanced illness management as well as the possible prospect of premature therapeutic interventions. Artificial intelligence also makes diagnosis cheaper and more accessible and affordable and provides early screening in more health facilities, even in resource-constrained settings.[54]

In the future, continued improvement in AI for medical diagnosis will be the key to future advancement in the management of neurodegenerative disease. Continued innovation in AI algorithms, convergence with personalized medicine, and innovation in wearable and remote monitoring devices will further enhance the promise of early detection. Effective clinical use of AI, however, will require overcoming data quality, ethical, and regulatory challenges[55]. AI scientists, clinicians, and policymakers will have to work hand in hand as a team to evaluate, standardize, and implement AI-based diagnostic approaches into existing healthcare practice without hitches[56]. As AI technology advances and becomes increasingly accepted, it can potentially revolutionize neurodegenerative disease diagnosis, paving the way for earlier intervention, improved patient management, and increased knowledge of these complex diseases.

ACKNOWLEDGMENT

I would like to extend my sincere appreciation to CNDR, and MIET for the excellent facilities throughout the production of this essay.

COMPETING INTERESTS

All authors declared the absence of any financial or personal conflicts pertaining to this work.

FUNDING

This study did not get any grants from any agency.

REFERENCES

1. Singh, P., et al., *General Introduction to Different Neurodegenerative Diseases*, in *Neurodegenerative Diseases*. 2025, CRC Press. p. 1-19.
2. Mauro, D., et al., *The role of early treatment in the management of axial spondyloarthritis: challenges and opportunities.* Rheumatology and Therapy, 2024. **11**(1): p. 19-34.
3. Valarmathi, P., et al., *Enhancing parkinson disease detection through feature based deep learning with autoencoders and neural networks.* Scientific Reports, 2025. **15**(1): p. 8624.
4. De Giorgi, R., et al., *12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.* EClinicalMedicine, 2024. **74**.
5. Gabrani, G., et al., *Revolutionizing healthcare: impact of artificial intelligence in disease diagnosis, treatment, and patient care*, in *Handbook on Augmenting Telehealth Services*. 2024, CRC Press. p. 17-31.
6. Khalifa, M., M. Albadawy, and U. Iqbal, *Advancing clinical decision support: The role of artificial intelligence across six domains.* Computer Methods and Programs in Biomedicine Update, 2024. **5**: p. 100142.
7. Chand, J. and G. Subramanian, *Neurodegenerative Disorders: Types, Classification, and Basic Concepts*, in *Multi-Factorial Approach as a Therapeutic Strategy for the Management of Alzheimer's Disease*. 2025, Springer. p. 31-40.
8. Proskauer Pena, S.L., *Cellular Mechanisms of Segregation and Consolidation of Memory in a Rat Model of Alzheimer's Disease.* 2025.
9. Gupta, A. and B. Sharma, *Neurodegenerative Diseases (ND): An Introduction*, in *Synaptic Plasticity in Neurodegenerative Disorders*. 2025, CRC Press. p. 3-20.
10. Kunwar, O.K. and S. Singh, *Neuroinflammation and neurodegeneration in Huntington's disease: Genetic hallmarks, role of metals and organophosphates.* Neurogenetics, 2025. **26**(1): p. 1-15.
11. Gadhave, D.G., et al., *Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance.* Ageing research reviews, 2024: p. 102357.
12. Chudzik, A., A. Śledzianowski, and A.W. Przybyszewski, *Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases.* Sensors, 2024. **24**(5): p. 1572.
13. Hatami-Fard, G. and S. Anastasova-Ivanova, *Advancements in Cerebrospinal Fluid Biosensors: Bridging the Gap from Early Diagnosis to the Detection of Rare Diseases.* Sensors, 2024. **24**(11): p. 3294.
14. Marques, M., A. Almeida, and H. Pereira, *The medicine revolution through artificial intelligence: ethical challenges of machine learning algorithms in decision-making.* Cureus, 2024. **16**(9).
15. Sarker, I.H., *Machine learning: Algorithms, real-world applications and research directions.* SN computer science, 2021. **2**(3): p. 160.
16. Cen, X., et al., *Towards interpretable imaging genomics analysis: methodological developments and applications.* Information Fusion, 2024. **102**: p. 102032.
17. Ogwu, M.C. and S.C. Izah, *Artificial Intelligence and Machine Learning in Tropical Disease Management*, in *Technological Innovations for Managing Tropical Diseases*. 2025, Springer. p. 155-182.
18. Rashid, M. and M. Sharma, *AI-Assisted Diagnosis and Treatment Planning—A Discussion of How AI Can Assist Healthcare Professionals in Making More Accurate Diagnoses and Treatment Plans for Diseases.* AI in Disease Detection: Advancements and Applications, 2025: p. 313-336.
19. Alam, T., et al., *Machine Learning in Healthcare: Key Applications and Insights from Recent Studies.*
20. Shah, H.H., *Early Disease Detection Through Data Analytics: Turning Healthcare Intelligence.* International Journal of Multidisciplinary Sciences and Arts. **2**(4): p. 252-269.
21. Rawat, A.S., J. Rajendran, and S.S. Sikarwar, *Introduction to AI in Disease Detection—An Overview of the Use of AI in Detecting Diseases, Including the Benefits and Limitations of the Technology.* AI in Disease Detection: Advancements and Applications, 2025: p. 1-26.
22. Singh, L., et al., *Ethical and Regulatory Compliance Challenges of Generative AI in Human Resources.* Generative Artificial Intelligence in Finance: Large Language Models, Interfaces, and Industry Use Cases to Transform Accounting and Finance Processes, 2025: p. 199-214.
23. Alabi, M., *AI-Assisted Medical Diagnosis Using Deep Learning and Computer Vision.* 2025.
24. Rashid, Z., et al., *The paradigm of digital health: AI applications and transformative trends.* Neural Computing and Applications, 2025: p. 1-32.
25. Ali, H., *AI in neurodegenerative disease research: Early detection, cognitive decline prediction, and brain imaging biomarker identification.* Int J Eng Technol Res Manag, 2022. **6**(10): p. 71.
26. Zhang, J., *Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson's disease.* npj Parkinson's Disease, 2022. **8**(1): p. 13.
27. Wasilewski, T., W. Kamysz, and J. Gębicki, *AI-assisted detection of biomarkers by sensors and biosensors for early diagnosis and monitoring.* Biosensors, 2024. **14**(7): p. 356.
28. Ahmed, H., et al., *Genetic variations analysis for complex brain disease diagnosis using machine learning techniques: opportunities and hurdles.* PeerJ Computer Science, 2021. **7**: p. e697.
29. Naik, A., A.A. Kale, and J.M. Rajwade, *Sensing the future: A review on emerging technologies for assessing and monitoring bone health.* Biomaterials Advances, 2024: p. 214008.
30. Sharma, D. and P. Kaushik, *Applications of AI in Neurological Disease Detection—A Review of Specific Ways in Which AI Is Being Used to Detect and Diagnose Neurological Disorders, Such as Alzheimer's and Parkinson's.* AI in Disease Detection: Advancements and Applications, 2025: p. 167-189.
31. Barker, M.S., et al., *Excessive emotional reactivity in a case of behavioral variant frontotemporal dementia with amyotrophic lateral sclerosis.* Psychiatry Research Case Reports, 2025. **4**(1): p. 100247.
32. Valerio, J.E., et al., *Advancing Early Identification of Clinical Trials in Neurosurgical Interventions for Parkinson's Disease: The Critical Role of AI-Driven Platforms and Technological Innovation.* 2025.
33. Mirabian, S., et al., *The potential role of machine learning and deep learning in differential diagnosis of Alzheimer's disease and FTD using imaging biomarkers: A review.* The Neuroradiology Journal, 2025: p. 19714009251313511.
34. Mehrotra, S., et al., *Advances and Challenges in the Diagnosis of Leishmaniasis.* Molecular Diagnosis & Therapy, 2025: p. 1-18.
35. Sedano, R., et al., *Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review.* Therapeutic Advances in Gastroenterology, 2025. **18**: p. 17562848251321915.
36. Yousra, K., *INTELLIGENT MONITORING OF AN INDUSTRIAL SYSTEM USING IMAGE CLASSIFICATION*. 2025, MINISTRY OF HIGHER EDUCATION.
37. Mishra, A., S.K. Sahu, and S. Mistry, *Role of computational biology in the diagnosis of neurodegenerative disorders*, in *Computational Intelligence for Genomics Data*. 2025, Elsevier. p. 167-179.
38. Faiyazuddin, M., et al., *The Impact of Artificial Intelligence on Healthcare: A Comprehensive Review of Advancements in Diagnostics, Treatment, and Operational Efficiency.* Health Science Reports, 2025. **8**(1): p. e70312.
39. Gholami, A., *Artificial Intelligence and Precision Medicine: Transforming the Landscape of Brain Tumors Treatment.*
40. Ajax, R. and M. Gimah, *AI-Driven Precision Medicine: Harnessing Big Data and Machine Learning to Tailor Treatments in Genomic Healthcare.* 2025.
41. Yarman, B.S. and S.P.S. Rathore, *The Future of AI in Disease Detection—A Look at Emerging Trends and Future Directions in the Use of AI for Disease*

Detection and Diagnosis. AI in Disease Detection: Advancements and Applications, 2025: p. 265-288.
42. Lyroi, E., et al., *AI-Powered Wearables: Transforming Remote Patient Monitoring.* 2025.
43. Olalekan Kehinde, A., *Leveraging Machine Learning for Predictive Models in Healthcare to Enhance Patient Outcome Management.* Int Res J Mod Eng Technol Sci, 2025. **7**(1): p. 1465.
44. Shen, Y., et al., *Twenty-Five Years of Evolution and Hurdles in Electronic Health Records and Interoperability in Medical Research: Comprehensive Review.* Journal of Medical Internet Research, 2025. **27**: p. e59024.
45. Yingngam, B., *4 AI-Driven Drug Discovery.* Machine Learning for Neurodegenerative Disorders: Advancements and Applications, 2025: p. 80.
46. Yilmaz, A., et al., *Lipidomics of Huntington's Disease: A Comprehensive Review of Current Status and Future Directions.* Metabolites, 2025. **15**(1): p. 10.
47. Pradeep, E., et al., *Empowering Social Media Users With Ethical AI*, in *Ethical AI Solutions for Addressing Social Media Influence and Hate Speech*. 2025, IGI Global Scientific Publishing. p. 91-118.
48. Reddy, S. and P. Mathur, *Translational AI: Bridging the Gap Between Research and Clinical Practice.* ScienceOpen Preprints, 2025.
49. Al Masaeid, T., et al., *Artificial Intelligence-Augmented Decision-Making: Examining the Interplay Between Machine Learning Algorithms and Human Judgment in Organizational Leadership.* Journal of Ecohumanism, 2025. **4**(1): p. 4683–4699-4683–4699.
50. Anil, S., et al., *Biomedical Imaging: Scope for Future Studies and Applications*, in *Multimodal Biomedical Imaging Techniques*. 2025, Springer. p. 319-338.
51. Yong, M.T.-T., S.-B. Ho, and C.-H. Tan, *Migraine generative artificial intelligence based on mobile personalized healthcare.* Journal of Informatics and Web Engineering, 2025. **4**(1): p. 275-291.
52. Onciul, R., et al., *Artificial intelligence and neuroscience: transformative synergies in brain research and clinical applications.* Journal of Clinical Medicine, 2025. **14**(2): p. 550.
53. Chen, Y.-M., et al., *Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence.* Journal of Biomedical Science, 2025. **32**(1): p. 16.
54. Patibandla, R.L., et al., *Proactive prognosis: Predicting the course of mental and neurological disorders with artificial intelligence*, in *Revolutionizing Medical Systems using Artificial Intelligence*. 2025, Elsevier. p. 75-92.
55. Panambur, S., et al., *Future directions for neurodegenerative disease management*, in *The Neurodegeneration Revolution*. 2025, Elsevier. p. 549-557.
56. Habibi, F., et al., *Harnessing artificial intelligence in Alzheimer's disease management: navigating ethical challenges in AI.* AI and Ethics, 2025: p. 1-17.

HOW TO CITE THIS ARTICLE: Pal S, Kaushik A, Goel F, Pal A, Garg VK. Revolutionizing Early Diagnosis: The Role of Artificial Intelligence in Neurodegenerative Disorders. *J Adv Sci Res*. 2025;16(03): 31-37 **DOI:** 10.55218/JASR.2025160306